EIT Health is calling for innovative digital and AI-powered medical technologies that are at an Innovation Maturity Level (IML) 6 and ready for clinical validation and market launch. Selected projects will be awarded funding to run pivotal clinical studies, collect real-world evidence to demonstrate safety and efficacy, apply for regulatory approval, and prepare for market commercialisation.
EIT Health will co-fund collaborative SME- or industry-led projects that focus on new market entry (either first market deployment, or expansion into a new market) and commercial piloting activities for patient-centered digital medical devices (DMDs) and in-vitro diagnostic devices (IVDDs).
Projects should focus on generating robust data to demonstrate economic and commercial viability, and improve market access conditions, through:
The Innovation Uptake Call invites organisations from across the Knowledge Triangle (Industry, Education and Research) to submit applications for funding for collaborative projects focused on patient-centric digital health solutions starting at Innovation Maturity Level (IML) 7 – Validation of Solution.
Proposed solutions must go beyond the state-of-the-art, have a clear medical purpose, and meet the definition of a digital medical device or in-vitro diagnostics device according to European regulations MDR 2017/745 and IVDR 2017/746. Proposals must address a critical, unmet healthcare need and harness digital technologies. They should demonstrate tangible health outcomes to patients across one or more stages of the patient care pathway, whether through screening, diagnosis, treatment and/or monitoring.
These devices could include software intended to be used alone or in combination with hardware (e.g. scanners, sensors, monitors, etc.) and include static and self-learning algorithms (e.g. artificial intelligence, machine learning). They can be used by patients, caregivers, healthcare professionals and health system users in the broadest sense.
The following types of innovations are out of scope:
These innovations should have already obtained formal regulatory approval (e.g. CE mark) and demonstrated some early market traction. They should now be at the stage of running real-world commercial pilots, building partnerships and generating additional robust evidence. This evidence can be used to demonstrate the solution’s relevance in the target market, demonstrate economic and commercial viability, test market access conditions, usage, and adoption by healthcare providers, patients and payors.
The total available budget under this call is €5.200.000.
Projects may request up to €650.000 in EIT Health funding. If the Commercialising Entity of the project is a micro or small enterprise, it must be allocated no less than €400.000 and no more than € 500 000 of grant funding from EIT Health.
EIT Health will fund a maximum of 50% of the project’s total costs, up to the maximum EIT Health funding. The consortium must secure the remaining 50% co-funding from other sources.
Up to 8 projects may be awarded, subject to the quality of the proposals.
If the Commercialising Entity qualifies as a micro or small enterprise, it must demonstrate a minimum level of financial traction of at least €500.000 in the past 3 years from external funding (revenue, equity, or other dilutive sources). Grants or non-dilutive sources do not count against this threshold.
Projects should last maximum 15 months, with an effective start date on 01 January 2027.
In accordance with the Horizon Europe Work Programme, to be eligible for funding, the applicant must be established in one of the eligible countries, i.e.:
Legal entities, which are established in countries not listed above will be eligible for funding if their participation is considered essential for implementing the action by the EIT.
Consortium composition
Consortia must include at least 2 legal entities independent from each other, and each legally established in a different country.
At the time of proposal submission, the proposed solution must be at an Innovation Maturity Level(IML) of either IML 7 (Validation of Solution) or IML 8 (Approval & Launch) with an obtained CE mark and be preparing for entry into a new market within the activity timeframe. Solutions at earlier IML stages are ineligible.